Eli Lilly (LLY) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration (FDA) after a panel voted to...
) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration after a panel voted to recommend its use. BMO Capital Markets Managing Director Evan Seigerman joins Market Domination to discuss how the drug will fit into the drug market .
They slow the cognition and function declines that we see when it comes to Alzheimer's disease, you get about six months of kind of a benefit which frankly, if your parent had it, that would be a really good thing.It's infusions that are, you know, twice a month.So it is, there's a lot of infrastructure.
So it's a lot of infrastructure um to get these patients the drug when you, and when you try to look at this, the mark of these treatments for Alzheimer's and you try to model it, like, how big is it now?I think over time between these two products, it could be 1015 $20 billion.
So there is opportunity elsewhere outside of metabolic disease and, and finally, one, you, you just look at the stock and it's just a monster.So, so what are the next catalysts?Why do we Yeah, why do we keep liking the stock?
Food And Drug Administration BMO Capital Markets Drug Market Market Domination Evan Seigerman New Alzheimer's Treatment Managing Director
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatmentAn FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
Read more »
FDA panel votes to recommend Eli Lilly's Alzheimer's drugA US Food and Drug Administration (FDA) panel voted unanimously 11-0 to recommend the approval of Eli Lilly's (LLY) Alzheimer's drug, donanemab. Yahoo...
Read more »
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffsExplore stories from Atlantic Canada.
Read more »
China Clears Eli Lilly’s Weight-Loss Drug, Only for Diabetes NowChina gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight-loss drugs in the world’s second-largest market.
Read more »
Eli Lilly exec on weight-loss drugs: 'It's not just a flash in the pan'Eli Lilly may be riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5...
Read more »
Alphabet taps Eli Lilly executive as new CFO replacing PoratAlphabet Inc. named Eli Lilly & Co. executive Anat Ashkenazi as its new chief financial officer, replacing Ruth Porat who announced last year she planned to step down.
Read more »